0:00
1:34 Remarkable changes in the treatment of GPA.
2:34 The role of Rituximab.
4:57 In your practice what markers do you look at to make your decisions?
8:23 Putting out the fire of inflammation. But what about the “embers”?
9:18 Induction and maintenance therapy.
11:15 The issue of not having GPA come back again.
13:10 Managing subglottic and tracheal stenosis when flaring.
17:12 Clinical features of ANCAassociated vasculitis.
18:44 GPA and MPA
19:06 Subclassifying AAV: clinical and prognostic information
20:32 Treatment of ANCAassociated vasculitis
21:55 Could you comment on the use of bactrim in the treatment of subglottic stenosis?
25:00 Explaining Bactrim.
27:29 Is there any updated information on Avocopan and combining it with prednisone, or rituximab?
31:06 Avocopan has been wellstudied with ANCApositive patients. Can you comment on testing Avocopan with ANCAnegative vasculitis?
39:11 What are the longterm effects of rituximab on young adults?
42:17 Research into possible treatment for people allergic to rituximab.
42:46 Looking into CAR Tcell therapy.
44:06 What do you think of a chronic low dose of prednisone?
52:44 What are some early symptoms of subglottic stenosis?

Granulomatosis with Polyangiitis
Recorded July 2023

In a Q&A format, Drs. Merkel, Berti, and Stein answer general questions from the audience about GPA, treatments, new ideas in research, individual manifestations and the progress that has been made over the years.  Peter A. Merkel, MD, MPH University of Pennsylvania.

Expand your knowledge of vasculitis. Visit the Vasculitis Foundation website at: https://www.vasculitisfoundation.org/